Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival

Consuelo Amantini*, Maria Beatrice Morelli1,2, Massimo Nabissi2, Francesco Piva3, Oliviero Marinelli1,2, Federica Maggi4, Francesca Bianchi5, Alessandro Bittoni5, Rossana Berardi5, Riccardo Giampieri5 and Giorgio Santoni2*

1 School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy, 2 School of Pharmacy, Experimental Medicine Section, University of Camerino, Camerino, Italy, 3 Department of Specialist Clinical and Odontostomatology Sciences, Polytechnic University of Marche, Ancona, Italy, 4 Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy, 5 Oncology Clinic, AOI Ospedali Riuniti, Polytechnic University of Marche, Ancona, Italy

The interest in liquid biopsy is growing because it could represent a non-invasive prognostic or predictive tool for clinical outcome in patients with pancreatic ductal adenocarcinoma (PDAC), an aggressive and lethal disease. In this pilot study, circulating tumor cells (CTCs), CD16 positive atypical CTCs, and CTC clusters were captured and characterized in the blood of patients with PDAC before and after palliative first line chemotherapy by ScreenCell device, immunohistochemistry, and confocal microscopy analysis. Gene profiles were performed by digital droplet PCR in isolated CTCs, five primary PDAC tissues, and three different batches of RNA from normal human pancreatic tissue. Welsh’s t-test, Kaplan-Meier survival, and Univariate Cox regression analyses have been performed. Statistical analysis revealed that the presence of high CTC number in blood is a prognostic factor for poor overall survival and progression free survival in advanced PDAC patients, before and after first line chemotherapy. Furthermore, untreated PDAC patients with CTCs, characterized by high ALCAM, POU5F1B, and SMO mRNAs expression, have shorter progression free survival and overall survival compared with patients expressing the same biomarkers at low levels. Finally, high SHH mRNA levels are negatively associated to progression free survival, whereas high vimentin mRNA levels are correlated with the most favorable prognosis. By hierarchical clustering and correlation index analysis, two cluster gene signatures were identified in CTCs: the first, with high expression of VEGFA, NOTCH1, EPCAM, IHH, is the signature of PDAC patients before chemotherapy, whereas the second, with an enrichment in the expression of CD44, ALCAM, and POU5F1B stemness and pluripotency genes, is reported after palliative chemotherapy. Overall our data support the clinical value of the identification of CTC’s specific biomarkers to improve the prognosis and the therapy in advanced PDAC patients.

Keywords: circulating tumor cells, pancreatic cancer, overall survival, gene signature, digital droplet PCR, atypical CTC
INTRODUCTION

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal disease whose incidence rate is growing. The overall survival (OS) rate at 5 years is only 9%, the lowest percentage with respect to other cancers (1). After diagnosis only 24% of patients survive 1 year and the 85% of them die within 5 years from diagnosis (2). This high death rate depends not only on the development of drug resistance, but also on late diagnosis. The majority of PDAC patients are treated with a first line palliative chemotherapy to reduce symptoms and prolong their survival (3). However, data obtained using combined therapy with gemcitabine plus paclitaxel or folirinox, have demonstrated an increase in the chemotherapeutic efficacy (4, 5).

In PDAC, the development of metastases occurs very early and their presence is discovered already during the first diagnosis. Metastases represent the main cause of cancer-related deaths and the mechanisms of the metastatic spread are not yet well-known. Recently, the detection/isolation of circulating tumor cells (CTCs) in blood samples from cancer patients prompted high interest. CTCs, believed to be responsible for seeding and dissemination of cancer, originate from the primary tumor mass and spread in the peripheral circulation among immune cells and erythrocytes (6). In addition, CTCs are also able to aggregate forming clusters, termed circulating tumor microemboli, whose size and concentration have been found to influence the development of metastases. It is now accepted that CTC clusters have survival advantage in the circulation, since the aggregation protect tumor cells from apoptosis, shear stress, and immune response facilitating the colonization (7). Thus, CTCs have been utilized as prognostic or predictive tool for clinical outcome in patients with localized, metastatic and recurrent disease and the CTC number is now considered a prognostic factor in breast, colorectal, prostate, and lung cancers (8).

Among the different technologies employed to isolate and purify CTCs, the ScreenCell® microfiltration is an epitope-independent size-based device, able to capture CTCs, both EPCAM positive and negative. It has been used in CTC identification in rare tumors like hemangiopericytoma (9) as well as in more common tumors such as non-small cell lung, bladder, prostate, head, and neck cancers (10–13) including PDAC (14).

Several studies demonstrated that a large number of CTCs and circulating tumor microemboli is detected in blood samples from PDAC patients with high accuracy and this appears to be clinically relevant avoiding the need of invasive tumor biopsies (8, 15, 16). In this regard, Nagrath et al. by using the CTC-chip on blood samples from PDAC patients, identified the presence of CTCs in the 100% of cases and the number of CTCs detected ranged from 9 to 831/ml (17). CTCs are found in the blood of patients with all PDAC stages and their presence is associated with poor progression-free survival (PFS), shorter OS, liver metastases, and poor tumor differentiation (18–20). Remarkably, high number of CTCs and unfavorable number of CTC clusters are associated with a trend for short OS (21).

Moreover, the recurrence occurs earlier in patients with CTCs than those without them, suggesting that CTCs are involved in pancreatic cancer malignancy and can be used to predict outcome and prognosis (18, 20). In addition, preclinical studies, performed using a xenograft mouse model of pancreatic adenocarcinoma, demonstrated that CTC concentration is markedly reduced in the pharmacologically treated group compared to the untreated one, indicating CTCs as a promising biomarker to monitor treatment efficacy (22). Interestingly, a recent report showed that in the blood of PDAC patients, the CTC population is represented not only by cancer cells but also by atypical CTCs that are hybrid cells, also called tmacrophages, deriving from the fusion between macrophages and cancer cells (23, 24). It has also been shown that the presence of tmacrophages significantly correlates with advanced PDAC disease (23).

At present, little is known about the neoplastic features, clinical significance, and molecular profiles of CTCs in PDAC patients. Several altered signaling pathways have been found in pancreatic cancers as KRAS, EGFR, NOTCH, WNT, and Hedgehog signaling pathways (25, 26). However, specific biomarkers useful for the early detection or for predicting treatment response are still missing. The complexity to manage clinical situations absolutely needs of new therapeutic strategies and further efforts must be made to identify novel targets for the development of personalized treatment options (27). In addition, given the anatomical difficulty of reaching the primary site of the tumor, it is problematic to monitor disease progression by invasive repeated biopsies. Thus, a multimarkers’ analysis represents a good strategy to better understand the features of CTCs in terms of aggressiveness and phenotype. This could make it possible to select the most effective treatment and to facilitate a personalized therapy.

The aim of this study was to evaluate the expression of different genes involved in several signaling pathways in CTCs, isolated from patients with metastatic PDAC, in order to correlate the gene expression profiles with clinical parameters, before and after the palliative chemotherapeutic treatments.

MATERIALS AND METHODS

Patient Recruitment and Sample Processing

The study population consisted of patients with a histologically/cytologically confirmed diagnosis of metastatic/locally advanced PDAC, who were candidates to receive 1st line palliative chemotherapy (n = 20) and with ages between 44 and 76, hospitalized from 2016 to 2018 at Università Politecnica delle Marche—Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I—Lancisi—Salesi, Ancona, Italy. Scheduled evaluations of disease status were performed via computed tomography scan of the chest and abdomen. Database with demographic, pathologic, and relevant clinical outcome/survival variables was maintained in a prospective manner. RECIST 1.1 criteria were used to evaluate the radiological responses to treatment, at approximately 3 months after the beginning of 1st line chemotherapy and every 3 months thereafter. Data regarding OS (time between the diagnosis and the death or lost-at-follow-up visit), OS1 (the time between the 1st cycle of chemotherapy and death or lost-at-follow-up visit) and PFS (the time between the 1st
cycle of chemotherapy and the 1st radiological progression or lost-at-follow-up-visit) were collected. All patients gave their consent prior to blood draws and the local Ethical Committee approved the study.

Peripheral blood samples from patients (6 ml) were collected in a K2-EDTA tube, before and after 3 months the beginning of the chemotherapy. The blood samples were processed within 3 h by using ScreenCell devices (Sarcelles, France) according to the protocol with some modifications to better eliminate peripheral blood cells. Briefly, after filtration, ScreenCell filters were washed with RPMI 1640 medium and then with Red Blood Lysis Buffer (Miltenyi Biotec, Bologna, Italy). The isolated cells were then detached from the filter by pipetting, collected in RPMI medium and the resulting cell suspension was filtered again. Blood samples from 5 healthy donors were processed as negative control.

Cell Counting
CTCs, collected in the second filter, were observed by stereomicroscope with bright-field illumination. Two independent operators performed a blind evaluation for each sample of the selected isolated cells, dividing patients in two categories: those with more than 10 CTCs and those with less. The presence of CTC clusters was also assessed and patients were divided in positive (Yes) or negative (No) for this parameter.

RNA Extraction, Reverse Transcription, and Digital Droplet PCR (ddPCR)
Total RNA from isolated CTCs was extracted by using the Single Shot Cell Lysis Kit (Bio-Rad, Hercules, CA, USA) according to the protocol. As control, three different total RNAs from normal pancreas tissues were purchased (OriGene Technologies, Rockville, MA, USA) and total RNA was extracted from 5 different primary PDAC tissue specimens, not autologous to the patients from whom CTCs were isolated (from Università Politecnica delle Marche—Azienda Ospedaliero-Università Ospedali Riuniti Umberto I—Lancisi—Salesi, Ancona), by “RNeasy® FFPE” kit (QIAGEN, Milan, Italy).

Total RNA was retro-transcribed by Iscript Advanced cDNA Synthesis kit (Bio-Rad) and the resulting cDNA was used to pre-amplify each sample for all primers used in the gene expression analysis by SSOADVancedPreAmp Kit and PrimePCRPreAMP Assays (Bio-Rad). The ddPCR Supermix for Probes (No dUTP) (Bio-Rad) and the specific PrimePCR™ ddPCR™ Expression Probe Assays conjugated with FAM or HEX fluorescent dyes (the same pool used in the pre-amplification step) (Bio-Rad) were then used to perform the ddPCR. The analyzed target genes were: CD44, DHH, ALCAM, IHH, VEGFA, NOTCH1, VEGFB, PTCH1, ZEB1, PTCH2, ZEB2, SHH, EPCAM, SMO, POU5F1B, SPARC, STAT3, vimentin (VIM), and NOTCH2. Data, normalized to β-actin concentration, were analyzed using the QuantaSoft Software (Bio-Rad). Since some of the analyzed transcripts could also be expressed, although at low levels, in normal blood cells, ddPCR analysis was carried out identifying the gene expression values obtained from white blood cells and taking them as negative threshold.

After ddPCR, according to the ROC analysis performed before and after palliative 1st line chemotherapy, patients were subgrouped for each gene in high (H) and low (L) expression.

Heat-maps were generated with hierarchical clustering analysis by the software Multi Experiment Viewer (MeV) Version 4.9.0. To compare CTCs with PDAC biopsies, gene expression levels were expressed as fold changes respect to normal pancreas RNAs used as calibrator.

Immunohistochemistry
Purified CTCs were fixed by using paraformaldehyde (4%) for 5 min at room temperature. After washing with PBS, cells were permeabilized by using 0.3% Triton X-100 in PBS for 15 min at room temperature. To block endogenous peroxidase, samples were incubated with 0.3% H2O2 for 15 min and then the blocking solution (3% BSA, 0.3% Triton X-100 in PBS) was used for 60 min at room temperature. Thereafter, cells were firstly incubated with anti-human pancytokeratin antibody (pan-CK, 1:50, DAKO, Agilent, Santa Clara, CA, USA) overnight at 4°C and then with anti-mouse biotin-conjugated secondary antibody for 30 min (1:200, ThermoFisher Scientific, Waltham, MA, USA). The immunodetection was performed using the VECTASTAIN® Elite® ABC System (Vectorstain Laboratories, Burlingame, CA, USA), according to the provided protocol and counterstaining.

Number of patients 20

| Average age | 64.04 ± 8.07 |
| Median age | 64.13 |
| Sex | F (4) M (16) |
| T | T1 (1) T2 (6) T3 (8) T4 (5) |
| N | Yes (16) No (4) |
| M | Yes (13) Liver (8) Lung (1) Peritoneum (1) Liver + lung (1) Liver + peritoneum (1) Lung + peritoneum (1) No (7) Yes (4) No (16) |
| Chirurgical resection | Yes (4) No (1) |
| First-line chemotherapy | Yes (19) Gemcitabine (4) FOLFIRINOX (4) Gemcitabine + abraxane (11) No (1) |

TABLE 1 | Patient demographics and clinical features.
with hematoxylin for 30 s. Four random fields of each filter were analyzed under 40X magnification using the Olympus BX51 Microscope and the ImageJ software (National Institutes of Health, Bethesda, MD, USA).

Confocal Microscope Analysis
Isolated CTCs were fixed with 4% paraformaldehyde for 5 min at room temperature and permeabilized as above described. For epithelial markers analysis, cells were stained with mouse anti-human pan-CK (1:50, Agilent), anti-human EPCAM (1:50, Cell Signaling Technology, Danvers, MA, USA), anti-human CD45, and anti-human CD16 (Cell Signaling Technology) antibodies followed by goat anti-mouse secondary antibody Alexa 594 (1:100, ThermoFisher Scientific), labeled with DAPI (ThermoFisher Scientific) and examined under 40X magnification using the Confocal Microscopy Nikon C2plus and the NIS software (Nikon, Otawara, Japan).

Statistical Analysis
This study was an exploratory research. Statistical analysis was performed by using the Welch’s t-test (GraphPad). Patients were divided in two groups according to: high and low CTC/cluster number, high and low gene expression levels. In addition, the Welch’s t-test was used to compare gene expression levels between PDAC biopsy and CTCs. $p < 0.05$ was considered as statistically significant. The Kaplan-Meier (KM) method was also used for survival analysis. For Univariate analysis of significance (MedCalc package, MedCalc® v16.4.3), the long-rank test or Cox analysis was used. $p < 0.05$ was considered as statistically significant.

We determined, by Relative Operating Characteristic (ROC) curve analysis, the expression value for each analyzed gene (cDNA copies/µl) that best discriminates between good and poor prognosis.

For hierarchical clustering, we applied the most common settings that is “average linkage” as agglomeration rule and Pearson correlation to measure the similarity among gene profiles.

The analysis of frequency distribution was performed using Chi-squared test selecting as expected frequencies $< 60$ for age, male category for sex, yes for lymph node invasion, yes for distant metastasis and high for CTC number; $p < 0.05$ was considered as statistically significant. To study the survival time we considered: OS, OS1, and PFS.

RESULTS
Capture and Detection of CTCs From Blood of PDAC Patients
All the 20 patients, enrolled in this study, had histologically confirmed diagnosis of PDAC; the list of patients’ characteristics, including average age, sex, TNM classification, chirurgical resection, and 1st line chemotherapy options, is shown in Table 1. The median OS, OS1, or PFS of the patient population were 11.87, 8.75, and 6.16 months, respectively. The KM analysis was carried out to evaluate OS and PFS in relation to the clinic-pathological characteristics of PDAC patients. No statistical significance was found among age, TNM stage, different 1st line palliative chemotherapy protocol and OS, OS1, and PFS. Sex showed positive correlation with PFS ($p = 0.0470$) (Supplementary Table 1).

CTCs were isolated from blood samples in patients before chemotherapy (20 patients) and after standard palliative 1st line chemotherapy (19 samples, since one patient died during treatment).

Both single CTCs and/or CTC clusters were captured by microfiltration. In particular, before chemotherapy, low CTCs number (<10 CTCs/ml blood) was evidenced in 6/20 (30%) and high number (more than 10 CTCs/ml blood) in 14/20 (70%) of the PDAC patients; 3 months later, after palliative chemotherapy, low CTCs number was found in 4/19 (21%) and high in 15/19 (79%) PDAC patients. Moreover, since

![FIGURE 1](image-url)
CTC clusters, composed by more than 3 cells, have a greater predisposition of forming distal metastasis than single CTCs (7), our attention was focused on the presence of CTC aggregates. CTC clusters were present in 13/20 (65%) patients before the chemotherapy and in 15/19 (79%) patients after palliative chemotherapy (Figure 1A). Neither single CTCs nor CTC clusters were found in the blood of healthy donors. After chemotherapy (T1), in three patients the number of CTCs was increased and in one was reduced. Regarding to CTC clusters, in five patients the number is increased and in other two they were reduced.

We confirmed the CTC phenotype by Hematoxylin and Eosin (H&E) staining, immunohistochemistry and confocal microscopy using anti-human pan-CK, anti-EPCAM, and anti-CD45 antibodies. The H&E staining evidenced, as previously described (15), that the single CTC displays a big size with a hyperchromatic nucleus larger than 14 µm and scant well-defined small rim of cytoplasm (Figure 1B). By immunohistochemistry, we showed that both single CTCs and CTC clusters, forming irregular microemboli, were markedly pan-CK+ (Figures 1C,D). Finally, the confocal microscopy analysis demonstrated the presence in the CTC population of both EPCAM+ or pan-CK+ CD45− cancer cells and EPCAM+ or pan-CK+ CD45+ atypical CTCs (Figure 2A). Since it has been suggested that atypical CTCs derived from the fusion between cancer...
cells and macrophages (23), we also evaluated, in CTCs, the expression of CD16 found to be expressed by protumorigenic macrophages (28). The isolated atypical CTCs expressed CD16 (Figure 2B) supporting the previous data about the origin of these hybrid cells. Finally, we demonstrated that CTC cluster is formed by both pan-CK\(^+\) CD45\(^-\) cancer cells and pan-CK\(^+\) CD45\(^+\) atypical CTCs (Figure 2C).

**Increased CTC Number Correlates With Poor Prognosis in PDAC Patients**

We found that, PDAC patients with high number of CTCs/ml (H), evaluated before the chemotherapy (T0), display a significant shorter survival respect to patients with low number (L) when considering OS and OS1 (Figures 3A,B). Concerning PFS, a tendency toward significance was found between high and low CTCs number (Figure 3C). Our results suggest that high number

![Figure 3](http://www.frontiersin.org)

**FIGURE 3 |** OS, OS1, and PFS according to CTC or CTC cluster number. (A–C) OS, OS1, and PFS were evaluated stratifying patients according to H (High, more than 10 CTCs/ml) or L (Low, \(< 10\) CTCs/ml) CTCs amount. (D–F) OS, OS1, and PFS, were evaluated stratifying patients according to presence (Yes) or not (No) of CTC clusters. \(p < 0.05\) was considered as statistically significant.

![Figure 4](http://www.frontiersin.org)

**FIGURE 4 |** Gene expression profiles of CTCs from PDAC patients. (A,B) Hierarchical clustering was used to analyze the expression levels of 19 genes, assessed by ddPCR, in CTCs from PDAC patients before chemotherapy (A) and after palliative chemotherapy (B). Two different main gene clusters were found, as shown with vertical bars and identified as 1 and 2, before chemotherapy (\(p < 0.0001\)) and after chemotherapy (\(p < 0.038\)). (C,D) Correlation matrix showing only the gene pairs whose expression levels were found to be positively correlated with a correlation coefficient more than 0.8500.
of CTCs represents a negative factor for survival in PDAC patients. No significant correlation between the presence of CTC cluster (T0) and OS, OS1, or PFS was observed (Figures 3D–F).

**Gene Expression Profile of CTCs in PDAC Patients**

The gene expression profile of CTCs from PDAC patients, before and after palliative chemotherapy, in PDAC biopsies and in normal pancreas RNAs, was evaluated.

At first, we found that the 19 genes analyzed by ddPCR analysis were differently expressed and clustered in the same patients, before and after therapy, as shown by the heat-map (Figures 4A,B). In fact, according to the expression levels, two different main gene clusters were identified in the hierarchical clustering before therapy: ZEB2, DHH, VEGFB, PTCH1, ZEB1, STAT3, SMO, SHH, PTCH2 (cluster 1) vs. CD44, IHH, VEGFA, NOTCH1, EPCAM, VIM, SPARC, NOTCH2, ALCAM, POU5F1B (cluster 2) (Figure 4A). Whereas, after 3 months of chemotherapy, the gene map showed a different grouping: ZEB2, SHH, VEGFA, NOTCH1, EPCAM (cluster 1) vs. DHH, VEGFB, PTCH1, ZEB1, STAT3, SMO, CD44, IHH, VIM, SPARC, NOTCH2, ALCAM, POU5F1B, PATCH2 (cluster 2) (Figure 4B). Since the gene grouping, based on the expression profiles, changes after chemotherapy, our data suggest that the treatment is able to modify the gene expression levels in CTCs. The analysis of the correlation index for all studied genes (data not shown) also confirmed the presence of a strong association in the expression levels of specific genes and two different gene signature models for CTCs from PDAC patients were built before and after palliative chemotherapy, respectively. The VEGFA/EPCAM/NOTCH1/IHH network of functional genes marks the PDAC patients before chemotherapy (Figure 4C), whereas the VEGFB/ALCAM/PTCH1/2/POU5F1B/CD44 cluster characterizes CTCs from patients after the conditioned chemotherapy (Figure 4D).

Moreover, since CTCs are implicated in the metastatic spread, to better understand the differences between circulating and primary tumor mass cells, we compared the gene expression levels, evaluated as fold changes respect to normal pancreatic RNAs, of CTCs (T0) with PDAC biopsies. A significantly increased expression of ALCAM, SHH, IHH, PTCH1, PTCH2, ZEB2, SMO, VIM, EPCAM, POU5F1B, STAT3, and NOTCH1 was found in CTCs respect to normal pancreatic RNA and, even more interestingly, compared with PDAC biopsies (Figure 5). Overall, these results suggest that the ability of CTCs to circulate is associated with the enhancement in the expression levels of various genes.
several genes mainly involved in the Hedgehog, angiogenesis, epithelial mesenchymal transition (EMT) and transcription regulation pathways.

**Detection of Different EMT Phenotypes in CTCs From PDAC Patients**

Among all the analyzed genes, our attention was focused on those strongly associated with the stemness and aggressiveness as well as EMT phenotype. On the basis of EMT markers (e.g., EPCAM/VIM) we demonstrated that about 40% of patients display epithelial CTCs (E-CTCs), whereas 60% show hybrid CTCs (H-CTCs) expressing both EPCAM and VIM (Table 2). No change in the percentage of patients showing E-CTCs was found 3 months after chemotherapy (42%), whereas a reduction of those with H-CTCs (37%) as well as the occurrence of patients (21%) with mesenchymal CTCs (M-CTCs) was observed (Table 3). We then analyzed the distribution of patients, according to the clinicopathological features and the different EMT-phenotypes of CTCs, before and after palliative chemotherapy (Tables 2, 3). We found that before chemotherapy, the distribution of patients for age, gender, lymph node metastasis, distant metastasis, and CTC number was significantly different between E-CTC and H-CTC groups (Table 2); similarly, after palliative chemotherapy, as respect to lymph node metastasis and distant metastasis, E-, H-, and M-CTC groups were significantly different (Table 3). Moreover, 1/20 (5%) and 3/19 (16%) PDAC patients, before and after palliative chemotherapy, respectively, evidenced a more aggressive CTC phenotype, characterized by high levels of CD44/ALCAM (29).

**Correlation Between CTC Gene Expression and OS or PFS in PDAC Patients**

The correlation between the expression level of the 19 analyzed genes in CTCs and OS, OS1, and PFS was evaluated (Supplementary Tables 2, 3).

A statistically significant correlation was found for the expression of ALCAM, POU5F1B, and SMO and OS in CTCs from PDAC patients (Figure 6A); similar results were obtained by Univariate analysis (Figure 6B). No positive correlation was found for the other analyzed genes (Supplementary Tables 2, 3). Similarly, after palliative chemotherapy, low ALCAM and high VIM levels were correlated with a longer OS1 (Figure 7A). These data were confirmed by Univariate analysis (Figure 7B). Regarding the PFS, high VIM, and low SHH levels were associated with a shorter PFS (Figure 7C). Similar results were obtained for SHH ($p = 0.022$) by Univariate Cox regression analysis (Figure 7D).

**DISCUSSION**

The majority of cancer patients dies from metastasis, regardless of chemotherapy approaches. Current cancer treatments are usually determined on primary tumor instead that on metastasis or cancer cells in blood circulation. Since distant metastases are considered to be the end-result of CTCs, the molecular characterization of these cells, including both cancer cells and tumacrophages (23), represents a promising approach to better evaluate the prognosis and select the therapy (30).

The identification of specific gene profiles and phenotypic changes occurring in CTCs could result in a better understanding of the metastatic process and lead to more effective and targeted therapeutic strategies. To our knowledge, very few reports have evaluated gene expression in blood CTCs. Moreover, this is the first study in which size-based CTC isolation method was coupled with ddPCR not only to confirm the CTCs phenotypes, but also to evaluate gene profiles.

Herein, we demonstrated the presence of single CTCs, atypical CTCs, and CTC clusters in the blood of PDAC patients before chemotherapy and 3 months later palliative first line chemotherapy. Our data are in agreement with recent data showing the presence of atypical CTCs, characterized by the expression of EPCAM, pan-CK, and CD45, in several cancer types. According to recent findings, they are hybrid cells deriving from the fusion of macrophages and tumor cells and for this reason, they are called tumacrophages. These cells, characterized by the expression of epithelial and hematopoietic markers as cytokeratins, CD45, and CD16, display progressive malignant behavior and tumorigenic abilities, contributing to the metastatic spread (23, 24).

High number of single CTCs and CTC clusters was captured in the blood of PDAC patients before and after chemotherapy. However, with regard to variations in the CTC number and cluster between before and after chemotherapy, in the majority of

**Table 2** PDAC patient distributions according to EMT phenotypes of CTCs and clinic-pathological features before chemotherapy.

| Age (year) | Epithelial CTC (%) | Hybrid CTC (%) |
|-----------|--------------------|----------------|
| <60       | 5/20 (25%)         | 2/20 (10%)     |
| >60       | 5/20 (25%)         | 8/20 (40%)     |

| Gender    | Epithelial CTC (%) | Hybrid CTC (%) |
|-----------|--------------------|----------------|
| Male      | 10/20 (50 %)       | 8/20 (40%)     |
| Female    | 2/20 (10%)         | 2/20 (10%)     |

| TNM stage | Epithelial CTC (%) | Hybrid CTC (%) |
|-----------|--------------------|----------------|
| I         | –                  | 1/20 (5%)      |
| II        | 2/20 (10%)         | 4/20 (20%)     |
| III       | 5/20 (25%)         | 3/20 (15%)     |
| IV        | 3/20 (15%)         | 2/20 (10%)     |

| Lymph node metastasis | Epithelial CTC (%) | Hybrid CTC (%) |
|-----------------------|--------------------|----------------|
| Negative              | 1/20 (5%)          | 3/20 (15%)     |
| Positive              | 9/20 (45%)         | 7/20 (35%)     |
| Distant metastasis    |                     |                |
| Negative              | 5/20 (20%)         | 2/20 (10%)     |
| Positive              | 5/20 (25%)         | 8/20 (40%)     |
| Metastasis sites      |                     |                |
| Liver                 | 4/13 (30.8%)       | 3/13 (23.1%)   |
| Others                | 1/13 (7.6%)        | 5/13 (38.5%)   |
| CTC number            |                     |                |
| High                  | 8/20 (40%)         | 7/20 (35%)     |
| Low                   | 1/20 (5%)          | 4/20 (20%)     |
| CTC cluster           |                     |                |
| Yes                   | 7/20 (35%)         | 6/20 (30%)     |
| No                    | 3/20 (15%)         | 4/20 (20%)     |

*p < 0.01.
Amantini et al. CTC Biomarkers in Pancreatic Cancer

TABLE 3 | PDAC patient distributions according to the different EMT phenotypes of CTCs and clinic-pathological features after palliative chemotherapy.

|                          | Epithelial CTC | Hybrid CTC | Mesenchymal CTC |
|--------------------------|----------------|------------|-----------------|
|                          | 8/19 (42.1%)   | 7/19 (36.8%) | 4/19 (21.1%)    |
| TNM stage                |                |            |                 |
| I                        | 1/19 (5.3%)    | 1/19 (5.3%) |                 |
| II                       | 3/19 (15.8%)   | 2/19 (10.1%)| 1/19 (5.3%)     |
| III                      | 4/19 (21.1%)   | 3/19 (15.8%)|                 |
| IV                       | 1/19 (5.3%)    | 1/19 (5.3%) | 3/19 (15.8%)    |
| Lymph node metastasis    |                |            |                 |
| Negative                 | 3/19 (15.8%)   | 1/19 (5.3%) |                 |
| Positive                 | 6/19 (31.6%)   | 7/19 (36.9%)| 2/19 (10.1%)    |
| Distant metastasis       |                |            |                 |
| Negative                 | 4/19 (21.1%)   | 1/19 (5.3%) | 2/19 (10.1%)    |
| Positive                 | 4/19 (21.1%)   | 6/19 (31.6%)| 2/19 (10.1%)    |
| Metastasis sites         |                |            |                 |
| Liver                    | 3/12 (25%)     | 4/12 (33.3%)|                 |
| Other                    | 1/12 (8.3%)    | 2/12 (16.7%)| 2/12 (16.7%)    |
| CTC number               |                |            |                 |
| High                     | 6/19 (31.6%)   | 5/19 (26.3%)| 4/19 (21.1%)    |
| Low                      | 2/19 (10.1%)   | 2/19 (10.1%)|                 |
| CTC cluster              |                |            |                 |
| Yes                      | 6/19 (31.6%)   | 5/19 (26.3%)| 4/19 (21.1%)    |
| No                       | 2/19 (10.1%)   | 2/19 (10.1%)|                 |

*p < 0.01.

FIGURE 6 | OS according to gene expression levels in CTCs from PDAC patients before chemotherapy. (A) Patients were stratified according to ALCAM, POU5F1B, and SMO gene expression levels in H (High) and L (Low) expressing. (B) OS evaluated according to the ALCAM, POU5F1B, and SMO gene expression levels by Univariate analysis. *p < 0.05 was considered as statistically significant.

the patients, chemotherapy is not able to induce changes. Overall, we evidenced that increased CTC number represents a negative prognostic factor for poor OS and PFS in PDAC patients.

EMT process arises during pancreatic cancer progression generating highly tumorigenic stem cells, characterized by motility and invasiveness. Multiple studies reported that EMT/MET (mesenchymal epithelial transition) processes are common in CTCs (31). Due to the high heterogeneity and plasticity of metastatic PDAC cells, pancreatic cells often cross between an EMT to MET phenotype during the metastatic adaption (32). In this regard, Zhao et al. using the Can Patrol system, identified the presence of three distinct CTC phenotypes in PDAC patients: E-CTC, M-CTC, and E/M or H-CTCs. The CTC status correlated with lymph node invasion, TNM, and distant metastasis. In this study, KM survival analysis showed that patients with higher CTC count had significantly reduced OS and PFS compared with those showing lower CTC number (33). Moreover, by exploring the EMT phenomenon, it has been demonstrated that M-CTCs are associated with tumor progression and chemo-resistant cancer types (34). In this regard, we showed that E-CTCs and H-CSCs are found in PDAC patients before chemotherapy, whereas the M-CTCs subtype appears in chemotherapy-conditioned patients.

The identification of biomarkers in patients at high risk of poor prognosis might deserve additional/alternative therapeutic interventions also in advanced metastatic PDAC patients.
In this regard, isolation of CTCs from blood sample holds the promise of diagnosing and molecular profiling cancers. CTCs are thought to represent the intravasation tumor stage between the primary cancer and its distant metastases. Thus, by ddPCR assay, the molecular profile of genes, involved in EMT, angiogenesis, stemness and pluripotency, Hedgehog, Notch, and Stat pathways, have been evaluated in CTCs from PDAC patients before and after palliative chemotherapy, and compared with normal pancreatic RNAs and PDAC biopsies. We found a strong up-regulation of ALCAM, IHH, and SHH, NOTCH1, EPCAM, PTCH1, PTCH2, POUS5F1B, SMO and ZEB2, STAT3, and VIM genes in the CTCs compared to normal pancreatic samples and, in particular, respect to the biopsies. Moreover, using hierarchical clustering to analyze gene expression levels, two different gene clusters were identified in CTCs from PDAC patients, before and after palliative chemotherapy. In particular, the first group consisted of VEGFA, NOTCH1 and 2, EPCAM, IHH, CD44, ALCAM, VIM, SPARC, and POUS5F1B genes whereas the other consisted of VEGFB, DHH and SHH, PTCH1 and 2, ZEB1 and 2, SMO, and STAT3 genes. After chemotherapy, the VEGFA, NOTCH1 and EPCAM phenotype was maintained, whereas a phenotype enriched of stemness and pluripotency genes such as VEGFB, CD44, ALCAM, VIM, SPARC, and POUS5F1B genes whereas the other consisted of VEGFB, DHH and SHH, PTCH1 and 2, ZEB1 and 2, SMO, and STAT3 genes. After chemotherapy, the VEGFA, NOTCH1 and EPCAM phenotype was maintained, whereas a phenotype enriched of stemness and pluripotency genes such as VEGFB, CD44, ALCAM, NOTCH2, POUS5F1B, PTCH1 and 2, STAT3, DHH, IHH and SMO, SPARC, and VIM, emerged. To better characterize the gene clustering based on positive correlation, multiple correlation index analysis was performed. A significant high correlation coefficient for several gene pairs was found allowing the identification of specific gene signatures in CTCs from PDAC patients: VEGFA/NOTCH1/EPCAM/IHH gene cluster before chemotherapy and VEGFB/POUS5F1B/PTCH1/PTCH2/ALCAM/CD44 after palliative chemotherapy.

There is growing evidence that CTC population is extremely heterogeneous, with a small percentage of tumor cells, called cancer stem cells (CSCs) expressing CD44, ALCAM, POUS5F1B (35), able to proliferate and form new tumors. The presence of CSCs in tumors is associated with aggressive disease and poor prognosis (35). We showed high ALCAM, POUS5F1B, and SMO mRNA expression levels in CTCs that are predictive of poor OS in both untreated and treated PDAC patients. In addition, high SHH mRNA expression level in CTCs has been demonstrated to represent a negative factor for PFS.

CSCs express several markers such as CD44, CD166, POUS5F1B, EPCAM, NOTCH1 (36), and STAT3 (37). In this regard, we observed during PDAC progression, after palliative chemotherapy, an enrichment in the CTCs of the expression levels of stemness and pluripotency genes, as CD44, ALCAM, EPCAM, NOTCH1, POUS5F1B, PTCH1, or CSC drivers as VEGFB and STAT3.

The role of VEGFB in tumor progression remains controversial. In fact, although VEGFB overexpression predicts for increased distant metastasis and shorter OS in advanced cancers (38), it was also shown to delay tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis (39). VEGFB is a part of VEGFB/GSK-β3/PI3K-Akt/CD44 signaling pathway controlling stem cell renewal, differentiation and development (40). The CD44 induces the EMT and triggers the expression of POUS5F1B/OCT-4 stem cell marker, through the AKT/GSK-3β/β-catenin pathway (41). POUS5F1B/OCT-4 maintains pluripotency and self-renewal by interacting with STAT3 and the Hedgehog pathway. Its overexpression in PDAC induces cell proliferation, migration, invasion and gemcitabine resistance (GR) (42) and its expression correlates with the N1/M1 status and worse prognosis. In several KRAS mutated cancers, the CD44 molecule associates with ALCAM/CD166 promoting an aggressive phenotype that predicts worse outcome and increased risk of liver and lung metastasis (e.g., colon cancer) (29). In addition, high ALCAM levels are associated with poor survival.
early tumor relapse (43) and chemoresistance (44). Regarding the Notch pathway, down-regulation of NOTCH1 reduces PDAC invasiveness (45), whereas NOTCH2 silencing reduces the expression of ZEB1, reverts the EMT phenotype, down-regulates the CSC marker expression (e.g., CD44) and decreases the invasiveness of GR-cells (46). In line with these findings, we showed the presence of CTCs expressing CD44/CD166 in PDAC patients with liver and lung metastasis. Thus, the analysis of gene expression levels in CTCs could permit to identify in KRAS mutated PDAC, patients expressing the CD44/CD166 phenotype associated with higher risk to develop lymph node invasion and distant metastasis. In addition, CTCs’ characterization represents a non-invasive tool to identify, before palliative chemotherapy, patients predisposed to show GR-resistance, thus facilitating the design of individualized therapies.

Further support to our data, comes from in vivo experiments with metformin (met) treatment targeting several genes studied in our molecular analysis. In fact, met has been demonstrated to inhibit pancreatic intraepithelial neoplasia growth and the progression to PDAC, by reducing the CD44 or EPCAM stem cell marker expression in a transgenic mouse model (47).

On the contrary, we also showed that VIM expression positively correlates with a higher OS and PFS in PDAC patients after palliative first line chemotherapy. VIM, traditionally considered a marker of EMT, is also involved in angiogenesis, migration, invasion, metastasis, and drug-resistance (48, 49). For long time, high expression of VIM was only associated with poor prognosis in patients with different cancers (50). However, recently, high VIM expression was also correlated with a prolonged survival in endometrioid cancer patients (51) and better prognosis in ovarian cancer patients (46). This protective effect was explained by the role of VIM in the regulation of cancer cell-platinum resistance (52). Similarly to this study, it has been demonstrated that in Capan-1-GR cells the drug resistance is associated with VIM down-regulation (53). Thus, the increase of OS in patients showing CTCs with high VIM expression may be related to gemcitabine susceptibility in PDAC patients mainly treated with gemcitabine, alone or in combination with paclitaxel.

Overall, our data support the potential clinical value of CTCs from PDAC patients. CTC number, EMT/MET phenotype and molecular gene profile may contribute to the PDAC prognosis and therapy. Therefore, this study confirms that in PDAC high CTC number represents a negative prognostic factor, but also demonstrates that the identification of specific biomarkers could be useful to improve the prognosis and therapy in advanced PDAC patients. However, our pilot study includes a small sample size and large well-designed clinical trial is required to elucidate the real potential value of CTC gene profile in PDACs.

DATA AVAILABILITY

Data generated or analyzed during this study, with the only exception of correlation matrix analysis for all studied genes, are included in this published article and its additional information files. The whole correlation matrix is available from the corresponding author.

ETHICS STATEMENT

All patients gave their consent prior to blood draws and the local Ethical Committee of the Università Politecnica delle Marche–Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I, Lancisi, Salesi, Ancona, Italy, approved the study. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

CA contributed to the acquisition, analysis, interpretation of the data, and drafted the manuscript. MM and MN performed acquisition and interpretation of the data. FM and FB revised the manuscript. FP and OM were responsible for analysis. AB and RG participated to the acquisition of the data. RB contributed to the conception of the work and revised the manuscript. GS designed the work and drafted the manuscript.

FUNDING

Research reported in this publication was supported by AIRC IG 2014 (15821). MM was supported by the Fondazione Umberto Veronesi (Post-doctoral Fellowship 2018, 2019).

ACKNOWLEDGMENTS

A special thanks to Prof. Tomassoni for his support in immunohistochemical analysis.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2019.00874/full#supplementary-material

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. (2019) 69:7–34. doi: 10.3322/caac.21551
2. Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. (2019) 10:10–27. doi: 10.14740/wjion1166
3. Hidalgo M. Pancreatic cancer. N Engl J Med. (2010) 362:1605–17. doi: 10.1056/NEJMra0901557
4. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. (2011) 29:4548–54. doi: 10.1200/JCO.2011.36.5742
5. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. (2011) 364:1817–25. doi: 10.1056/NEJMoa1011923
6. Jeong KY, Kim EE, Park MH, Kim HM. Perspective on cancer therapeutics utilizing analysis of circulating tumor cells. *Diagnoses*. (2018) 8:23. doi: 10.3390/diagnostics8020023

7. Fabisiwicz A, Grzybowski E. CTC clusters in cancer progression and metastasis. *Med Oncol*. (2017) 34:12. doi: 10.1007/s12032-016-0785-0

8. Khajavi J, Backen A, Shone Y, Menasse L, Ryder D, Krebs M, et al. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. *Br J Cancer*. (2012) 106:508–16. doi: 10.1038/bjc.2011.545

9. Nicolazzo C, Colangelo L, Corsi A, Carpino G, Gradilone A, Sonato C, et al. Liquid biopsy in rare cancers: lessons from hemangiopericytoma. *Anat Cell Pathol*. (2018) 2018:9718585. doi: 10.1155/2018/9718585

10. Chudasama D, Barr J, Beeson J, Beddow E, McGonigle N, Rice A, et al. Detection of circulating tumour cells and survival of patients with non-small cell lung cancer. *Anticancer Res*. (2017) 37:169–73. doi: 10.21873/anticancerres.11302

11. Awe JA, Saranchuk J, Drachenberg D, Mai S. Filtration-based enrichment of circulating tumor cells: a cell motility gene signature that predicts survival after surgery. *BMC Cancer*. (2012) 12:527. doi: 10.1186/1471-2407-12-527

12. Harouaka R, Kang Z, Zheng S, Cao L. Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications. *Pharmacol Ther*. (2014) 141:260–9. doi: 10.1016/j.pharmthera.2013.10.004

13. Han L, Chen W, Zhao Q. Prognostic value of circulating tumor cells in patients with pancreatic cancer: a meta-analysis. *Clin Cancer Res*. (2015) 21:899–906. doi: 10.1158/1078-0432.CCR-14-0894

14. Albrecht I, Kopfstein L, Strittmatter K, Schomber T, Falkevall A, Hagberg CE, et al. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. *Acta Histochem*. (2010) 5:e14109. doi: 10.1371/journal.pone.0014109

15. Hidalgo M, Cascal S, Kleef J, Labianca R, Lohr JM, Neoptolemos J, et al. Addressing the challenges of pancreatic cancer: Future directions for improving outcomes. *Pancreatology*. (2015) 15:8–18. doi: 10.1016/j.pan.2014.10.001

16. Oliveira-Cuhna M, Newman WG, Siriwatdena AK. Epidermal growth factor receptor in CTC diagnostic cancer. *Cancers*. (2011) 3:513–6. doi: 10.3390/cancers30201513

17. Kim MA, Han L, Chen W, Zhao Q. Prognostic value of circulating tumor cells in patients with pancreatic ductal adenocarcinoma. *Pancreas*. (2017) 46:649–54. doi: 10.1097/MPA.0000000000000757

18. Poruk KE, Valero V III, Saunders T, Blackford AI, Griffin JF, Poling J, et al. Circulating tumor cell phenotype predicts recurrence and survival in pancreatic adenocarcinoma. *Ann Surg*. (2016) 264:1073–81. doi: 10.1097/SLA.0000000000001600

19. Han L, Chen W, Zhao Q. Prognostic value of circulating tumor cells in patients with pancreatic cancer: a meta-analysis. *Tumour Biol*. (2014) 35:2473–80. doi: 10.1007/s13277-013-0327-5

20. Zhang Y, Zhou N, Xu X, Zhang X, Li S, Lei Z, et al. Tumacrophage: macrophages transformed into tumor stem-like cells by virulent genetic material from tumor cells. *OncoTarget*. (2017) 8:82326–43. doi: 10.18632/oncotarget.19320

21. Hidalgo M, Cascal S, Kleef J, Labianca R, Lohr JM, Neoptolemos J, et al. Addressing the challenges of pancreatic cancer: Future directions for improving outcomes. *Pancreatology*. (2015) 15:8–18. doi: 10.1016/j.pan.2014.10.001
44. Hong X, Michalski CW, Kong B, Zhang W, Raggi MC, Sauliunaite D, et al. ALCAM is associated with chemoresistance and tumor cell adhesion in pancreatic cancer. *J Surg Oncol*. (2010) 101:564–9. doi: 10.1002/jso.21538

45. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarki FH. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. *Cancer Res*. (2006) 66:2778–84. doi: 10.1158/0008-5472.CAN-05-4281

46. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. *Ann Surg Oncol*. (2007) 14:3629–37. doi: 10.1245/s10434-007-9583-5

47. Mohammed A, Janakiram NB, Brewer M, Ritchie RL, Marya A, Lightfoot S, et al. Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling. *Transl Oncol*. (2013) 6:649–59. doi: 10.1593/txon.13556

48. Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. *Cell Mol Life Sci*. (2011) 68:3033–46. doi: 10.1007/s00018-011-0735-1

49. Huo Y, Zheng Z, Chen Y, Wang Q, Zhang Z, Deng H. Downregulation of vimentin expression increased drug resistance in ovarian cancer cells. *Oncotarget*. (2016) 7:45876–88. doi: 10.18632/oncotarget.9970

50. Liu LG, Yan XB, Xie RF, Jin ZM, Yang Y. Stromal expression of vimentin predicts the clinical outcome of stage II colorectal cancer for high-risk patients. *Med Sci Monit*. (2017) 23:2897–905. doi: 10.12659/MSM.904486

51. Zou S, Sun H, Fan L, Xiao X, Gong L, Zhu J, et al. Prognostic indicators in patients with early stage endometrioid adenocarcinoma: a retrospective case-control study of 523 patients. *Int J Clin Exp Med*. (2017) 10:3692–8.

52. Stübert S, Koper K, Ditzsch-Wicherek MM, Jozwicki W. High tumor cell vimentin expression indicates prolonged survival in patients with ovarian malignant tumors. *Ginekol Pol*. (2019) 90:11–9. doi: 10.5603/GP.2019.0003

53. Avan A, Quint K, Nicolini F, Funel N, Frampton AE, Mafouh M, et al. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. *Curr Pharm Des*. (2013) 19:940–50. doi: 10.2174/138161213804547312

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Amantini, Morelli, Nabissi, Piva, Marinelli, Maggi, Bianchi, Bittoni, Berardi, Giampieri and Santoni. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.